Robinhood Asset Management LLC Makes New $5.72 Million Investment in Neurocrine Biosciences, Inc. $NBIX

Robinhood Asset Management LLC purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 40,296 shares of the company’s stock, valued at approximately $5,715,000.

Other institutional investors and hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in Neurocrine Biosciences by 11.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,730,152 shares of the company’s stock worth $664,019,000 after acquiring an additional 468,405 shares during the period. AQR Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 83.7% in the third quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after purchasing an additional 1,263,633 shares during the period. Deerfield Management Company L.P. increased its stake in shares of Neurocrine Biosciences by 1.4% in the third quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock worth $166,258,000 after purchasing an additional 16,543 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Neurocrine Biosciences by 3.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 710,122 shares of the company’s stock worth $99,686,000 after purchasing an additional 25,683 shares during the last quarter. Finally, Armistice Capital LLC lifted its position in shares of Neurocrine Biosciences by 3.1% during the 3rd quarter. Armistice Capital LLC now owns 697,022 shares of the company’s stock worth $97,848,000 after purchasing an additional 20,998 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Trading Up 0.7%

Shares of NASDAQ NBIX opened at $132.48 on Tuesday. The firm has a market capitalization of $13.30 billion, a price-to-earnings ratio of 28.43, a PEG ratio of 0.69 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $84.23 and a one year high of $160.18. The business has a fifty day simple moving average of $131.52 and a 200 day simple moving average of $139.01.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Wednesday, February 11th. The company reported $1.88 earnings per share for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48). Neurocrine Biosciences had a return on equity of 16.48% and a net margin of 16.73%.The business had revenue of $805.50 million for the quarter, compared to analyst estimates of $804.21 million. During the same quarter in the prior year, the firm earned $1.69 EPS. The firm’s quarterly revenue was up 28.3% on a year-over-year basis. On average, research analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on NBIX shares. Wall Street Zen lowered Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Monday, February 16th. Wedbush increased their price objective on Neurocrine Biosciences from $149.00 to $151.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. BMO Capital Markets dropped their target price on shares of Neurocrine Biosciences from $147.00 to $140.00 and set a “market perform” rating on the stock in a research report on Thursday, February 12th. Truist Financial cut their target price on shares of Neurocrine Biosciences from $169.00 to $140.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Finally, HC Wainwright reduced their price target on shares of Neurocrine Biosciences from $198.00 to $192.00 and set a “buy” rating for the company in a report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $175.10.

Insider Buying and Selling at Neurocrine Biosciences

In related news, CEO Kyle Gano sold 36,400 shares of the company’s stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $132.70, for a total value of $4,830,280.00. Following the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at $18,632,008.90. The trade was a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 4.80% of the company’s stock.

Neurocrine Biosciences News Summary

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Acquisition expands Neurocrine’s commercial footprint by adding VYKAT XR (first/only FDA treatment for hyperphagia in Prader‑Willi Syndrome) and creates a three‑product commercial portfolio alongside INGREZZA® and CRENESSITY®. This supports long‑term revenue diversification. Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
• Positive Sentiment: Bank of America reiterated a Buy and raised its price target to $199, signaling bullish analyst conviction that the deal meaningfully increases upside despite a near‑term pipeline lull. Neurocrine Biosciences: Vykat XR Acquisition Unlocks Diversified Growth and Upside Potential Despite Near-Term Pipeline Lull
• Positive Sentiment: Needham reaffirmed a Buy with a $185 target, reinforcing that some buy‑side analysts view the acquisition as value‑creating. Needham & Company Reaffirms Buy on Neurocrine
• Neutral Sentiment: Deal mechanics: Neurocrine will pay $53.00 per Soleno share in an all‑cash transaction valued at about $2.9 billion; a conference call was held to discuss terms. These are execution/funding facts investors will monitor. Neurocrine to buy Soleno Therapeutics for $2.9 billion
• Neutral Sentiment: Market validation for the premium: Soleno shares jumped strongly on the deal, highlighting investor appetite for Soleno’s assets and the strategic rationale for Neurocrine. Soleno Therapeutics (SLNO) Soars 32% on $2.9-Billion Merger
• Negative Sentiment: Some analysts remain cautious: BMO kept a Hold and a $140 target, flagging long‑term execution risks for Ingrezza and orphan market rollouts that could offset acquisition benefits. Balanced View on Neurocrine Biosciences: Favorable Soleno Acquisition Prospects Offset by Long-Term Ingrezza and Orphan Market Execution Risks
• Negative Sentiment: Short‑term headwinds: Neurocrine’s stock initially dropped on the announcement (acquirer sell‑off is common after M&A news) as investors digest the $2.9B cash outlay, integration risk and near‑term pipeline cadence. This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal.
• Negative Sentiment: M&A call/transcript and analyst commentary highlight execution and integration questions investors should track (commercial roll‑out for VYKAT XR, orphan market uptake, and funding). Neurocrine Biosciences, Inc. (NBIX) M&A Call Transcript

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.